beta
Trial Radar IA
Lo studio clinico NCT07349498 (CORE-HCT) per Trapianto di cellule staminali ematopoietiche, Complicazione del trapianto, Eventi cardiovascolari è in arruolamento. Consulti la vista a schede del Radar degli Studi Clinici e gli strumenti di scoperta IA per tutti i dettagli. Oppure, ponga pure una domanda qui.
Un studio corrisponde ai criteri del filtro
Vista a schede
Torna alla ricerca

Cardiovascular Outcomes and Risk Evaluation Among Recipients of Hematopoietic Stem Cell Transplantation (CORE-HCT) 10.000 Osservazionale

In arruolamento
I dettagli dello studio clinico sono disponibili principalmente in inglese. Tuttavia, Trial Radar IA può essere d'aiuto! Basta cliccare su 'Spiega lo studio' per visualizzare e discutere le informazioni sullo studio nella lingua selezionata.
La sperimentazione clinica NCT07349498 (CORE-HCT) è uno studio osservazionale per Trapianto di cellule staminali ematopoietiche, Complicazione del trapianto, Eventi cardiovascolari, attualmente in arruolamento. Avviato il 1 gennaio 2026, prevede di arruolare 10.000 partecipanti. Sotto la guida di Peking University People's Hospital, dovrebbe concludersi entro il 31 dicembre 2036. I dati più recenti da ClinicalTrials.gov sono stati aggiornati l'ultima volta il 16 gennaio 2026.
Sommario breve
This is a prospective, multicenter observational study for recipients of hematopoietic stem cell transplantation. Patients who underwent hematopoietic stem cell transplantation at the participating centers will be entrolled in the study. The clinical characteristics, laboratory profiles, management measures, and clinical outcomes such as post-transplant cardiovascular events will be prospectively collected.
Titolo ufficiale

Cardiovascular Outcomes and Risk Evaluation Among Recipients of Hematopoietic Stem Cell Transplantation (CORE-HCT): A Prospective Multicenter Observational Study

Patologie
Trapianto di cellule staminali ematopoieticheComplicazione del trapiantoEventi cardiovascolari
Altri ID dello studio
  • CORE-HCT
  • 2025-z232
Numero NCT
NCT07349498
Data di inizio (effettiva)
2026-01-01
Ultimo aggiornamento pubblicato
2026-01-16
Data di completamento (stimata)
2036-12-31
Arruolamento (previsto)
10.000
Tipo di studio
Osservazionale
Stato
In arruolamento
Bracci / Interventi
Gruppo/Braccio di partecipantiIntervento/Trattamento
Patients undergoing hematopoietic stem cell transplantation
Patients who undergo allogeneic hematopoietic stem cell transplantation at participating medical center.
N.D.
Esito primario
Misure di esitoDescrizione della misuraArco temporale
Major adverse cardiovascular events (MACE)
Major adverse cardiovascular events (MACE) after hematopoietic stem cell transplantation.
At 30 days, 100 days, 3 months, 6 months, 1 years, 3 years, 5 years post hematopoietic stem cell transplantation.
Esito secondario
Misure di esitoDescrizione della misuraArco temporale
Cardiovascular events
Cardiovascular events after hematopoietic stem cell transplantation, such as cardiovascular death, ischemic heart disease, coronary artery disease, stroke, heart failure, arrhythmia cardiomyopathy, myocarditis, endocarditis, valvular heart disease, and pericardial disease.
At 30 days, 100 days, 3 months, 6 months, 1 years, 3 years, 5 years post hematopoietic stem cell transplantation.
Overall survival
Overall survival after hematopoietic stem cell transplantation.
At 30 days, 100 days, 3 months, 6 months, 1 years, 3 years, 5 years post hematopoietic stem cell transplantation.
Event-free survival
Events were defined as the occurrence of any of the following after allo-HSCT: grade III-IV acute graft-versus-host disease (GVHD), chronic GVHD requiring systemic immunosuppression, relapse or progression of the hematologic disease, or death from any cause during follow-up.
At 30 days, 100 days, 3 months, 6 months, 1 years, 3 years, 5 years post hematopoietic stem cell transplantation.
Complications of hematopoietic stem cell transplantation
Complications arising from hematopoietic stem cell transplantation range from early issues such as regimen toxicity and acute GVHD to late effects including chronic GVHD, organ dysfunction, and secondary malignancies.
At 30 days, 100 days, 3 months, 6 months, 1 years, 3 years, 5 years post hematopoietic stem cell transplantation.
Assistente alla partecipazione
Criteri di eleggibilità

Età idonea
Bambino, Adulto, Adulto anziano
Sessi idonei
Tutti
  • Patients who undergo hematopoietic cell transplantation at any of the participating medical centers.

  • Any other conditions that, in the opinion of the investigator, can interfere with the interpretation of data.
  • Patient request to withdraw from the study.
Peking University People's Hospital logoPeking University People's Hospital
Parte responsabile dello studio
Xiao Hui Zhang, Investigatore principale, MD, Peking University People's Hospital
Contatti principali dello studio
Contatto: Xiao Hui Zhang, 861088324577, [email protected]
16 Centri dello studio in 1 paesi

Beijing Municipality

Chinese PLA General Hospital, Beijing, Beijing Municipality, China
Dai Hong Liu, Contatto
In arruolamento
Peking University First Hospital, Beijing, Beijing Municipality, China
Yu Jun Dong, Contatto
In arruolamento
Peking University People's Hospital, Beijing, Beijing Municipality, China
Xiao Hui Zhang, Contatto, 861088324577, [email protected]
In arruolamento
Peking University Third Hospital, Beijing, Beijing Municipality, China
Hong Mei Jing, Contatto
In arruolamento

Chongqing Municipality

Xinqiao hospital of the third military medical university, Chongqing, Chongqing Municipality, China
Xi Zhang, Contatto
In arruolamento

Guangdong

Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, China
Yang Liang, Contatto
In arruolamento
Peking University Shenzhen Hospital, Shenzhen, Guangdong, China
Hong Yu Zhang, Contatto
In arruolamento

Heilongjiang

First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
Sheng Jin Fan, Contatto
In arruolamento

Henan

The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Zhong Xing Jiang, Contatto
In arruolamento

Hubei

Tongji Hospital, Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China
Yi Cheng Zhang, Contatto
In arruolamento
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Ling Hui Xia, Contatto
In arruolamento

Shaanxi

First Affiliated Hospital Xi'an Jiaotong University, Xi'an, Shaanxi, China
Peng Cheng He, Contatto
In arruolamento

Sichuan

Sichuan Provincial People's Hospital, Chengdu, Sichuan, China
Xiao Bing Huang, Contatto
In arruolamento

Tianjin Municipality

Hematology Hospital of Chinese Academy of Medical Sciences (Hematology Research Center of Chinese Academy of Medical Sciences), Tianjin, Tianjin Municipality, China
Er Lie Jiang, Contatto
In arruolamento

Xinjiang

First Affiliated Hospital of Xinjiang Medical University, Ürümqi, Xinjiang, China
Ming Jiang, Contatto
In arruolamento

Zhejiang

First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China
Yi Luo, Contatto
In arruolamento